Early Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 70 years, of any gender.
• People who have a specific genetic marker called HLA-A*11:01 (a result from a blood or tissue test).
• People who have been diagnosed with a type of lymphoma (a blood cancer) that tests positive for the Epstein-Barr virus (EBV), confirmed by a laboratory test of tumor tissue, and who also have a measurable amount of EBV in their blood.
• People whose lymphoma type includes, but is not limited to, NK/T-cell lymphoma, peripheral T-cell lymphoma, or other related types.
• People whose cancer has come back after previously going into full remission (relapsed), or whose cancer did not respond well enough to standard treatment (refractory), as defined by specific treatment response criteria.
• People with relapsed or refractory peripheral T-cell lymphoma or NK/T-cell lymphoma who have already received at least one prior course of treatment — and for NK/T-cell lymphoma, this must have included a specific type of chemotherapy containing a drug called asparaginase (and radiotherapy for certain early-stage nasal cases).
• People who have at least one area of cancer that is large enough to be measured on a scan (confirm with trial site for exact size requirements), or, in some cases, a significant number of cancer cells found in bone marrow testing.
• People whose blood counts, liver, kidneys, heart, and clotting function all meet minimum health thresholds, as confirmed by lab tests (confirm with trial site for exact values).
• People whose doctors estimate they are likely to survive for more than 3 months.
• People who are well enough to carry out basic daily activities, as measured by a standard medical scale called the ECOG score of 0, 1, or 2 (meaning not completely bedridden or severely limited).
• People who are not planning a pregnancy during the treatment period; women who could become pregnant must have a negative pregnancy test and agree to use effective contraception during the study and for 4 months after treatment ends.
• People who are willing to take part, are able to give signed consent, can follow the study plan, and have a suitable vein in their arm for collecting blood cells.

Who may not be able to join:

• People with a history of another type of cancer, unless it was a very early or minor skin or surface cancer, or another cancer that was fully treated with no return for at least 5 years (confirm with trial site).
• People who have received cancer treatment — such as chemotherapy, radiotherapy, targeted therapy, or immunotherapy — within the last 4 weeks, or palliative radiotherapy within the last 2 weeks.
• People who are currently pregnant or breastfeeding.
• People with serious medical conditions such as dangerously high pressure in the brain, significantly reduced consciousness, respiratory failure, or a severe blood clotting disorder called DIC.
• People with severe organ problems, including very poor heart function (NYHA class IV), severely reduced liver function (Child-Pugh class C), significantly reduced kidney function, or a resting blood oxygen level below 92%.
• People with certain active infections, including active hepatitis B or C under specific test conditions, HIV, syphilis, active tuberculosis or a past history of active tuberculosis, or other serious infections currently requiring treatment.
• People with active disease affecting the brain or central nervous system, such as cancer spread to the brain, brain infections, or conditions that require urgent treatment or high-dose immune-suppressing medications.
• People who are currently taking steroid medications (such as prednisone) taken by mouth or injection, and who are expected to need them long-term during the study — or anyone who has received such steroids within 72 hours before the planned cell infusion (skin creams or inhalers are generally not included; confirm with trial site).
• People who have a condition called graft-versus-host disease (GVHD) of a moderate or severe level, or who are currently taking medications to suppress the immune system.
• People with a known history of severe allergic reactions to any medications or ingredients used in this study, or a history of allergy to a drug called tocilizumab.
• People who have any other condition that the trial doctor considers would make participation unsafe or unsuitable.

Important: Always verify eligibility with the trial site directly before applying.